Zydus Cadila launches anti-ulcer drug in US
New Delhi: Zydus Cadila has launched mesalamine delayed release tablets, used for the treatment of ulcerative colitis, in the US market.
"Zydus Cadila has commercially launched its mesalamine delayed release tablets in the US market. Zydus was the first to file an Abbreviated New Drug Application (ANDA) for the generic version of Lialda," the company said in a BSE filing on Wednesday.
Zydus Cadila said this product is the only generic of Lialda available to patients in the US.
The Gujarat-based group has more than 130 USFDA approvals and has filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd